<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027348</url>
  </required_header>
  <id_info>
    <org_study_id>I 74018</org_study_id>
    <nct_id>NCT04027348</nct_id>
  </id_info>
  <brief_title>Palliative Management of Inoperable Malignant Bowel Obstruction</brief_title>
  <official_title>Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the role of palliative medical management of inoperable malignant bowel
      obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">March 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 7, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Obstruction Clearance</measure>
    <time_frame>Within 7 days of starting protocol therapy</time_frame>
    <description>Clearing of malignant bowel obstruction</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Malignant Bowel Obstruction</condition>
  <arm_group>
    <arm_group_label>Treatment (octreotide, dexamethasone, metoclopramide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (octreotide, dexamethasone, metoclopramide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (octreotide, dexamethasone, metoclopramide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (octreotide, dexamethasone, metoclopramide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years of age.

          -  Diagnosis of partial bowel obstruction secondary to active or prior malignancy
             (primary or metastatic GI, GYN, and carcinomatosis) caused either by tumor itself or
             adhesions inthe setting of active malignancy.

          -  Cross-sectional imaging performed within 24 hours of clinical symptoms of bowel
             obstruction (nausea, vomiting, and constipation ± abdominal pain) during hospital
             admission.

          -  Patient must have an inoperable MBO based on a surgical consult.

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             writteninformed consent form prior to receiving any study related procedure.

        Exclusion Criteria:

          -  Evidence of complete bowel obstruction by imaging.

          -  Bacteremia/septicemia with a documented positive blood culture: If a blood culture
             comes back positive after study enrollment, patient will be excluded.

          -  Patients already taking a steroid equivalent to 8 mg of dexamethasone per day prior to
             study enrollment.

          -  Patients undergoing bowel surgery or stent placement for bowel obstruction.

          -  Those patients with MBO in setting of incarcerated hernia.

          -  Known history of QT prolongation syndrome or if QTc is &gt; 450 msec in males or &gt; 470
             msec in females on baseline EKG within 2 weeks of enrollment.

          -  Lack of decision making capacity/delirium.

          -  Pregnant or nursing female participants.

          -  Actively suicidal patients.

          -  Acute cholecystitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Case, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Cahill, BS</last_name>
    <phone>716-845-1573</phone>
    <email>Beth.Cahill@roswellpark.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Cahill, BS</last_name>
      <phone>716-845-1573</phone>
      <email>Beth.Cahill@roswellpark.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bowel obstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

